Evidence map›Paper›PMID 38148879›Full record

ArticleJournal of psoriasis and psoriatic arthritis2022

Specialist and Patient Perspectives on Strategies to Improve Cardiovascular Disease Prevention Among Persons Living with Psoriatic Disease.

A C Gustafson, J M Gelfand, J Davies, A E Lieberman, J B Mason, A W Armstrong, A Ogdie, N N Mehta, J S Barbieri, R S Beidas

Open access · greenAbstract read
In one paragraph

Article in Journal of psoriasis and psoriatic arthritis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.2field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

A C GustafsonUniversity of Pennsylvania, Philadelphia, PA, United States.ORCID 0000-0001-8107-2791
J M GelfandDepartment of Dermatology, Perelman Center for Advanced Medicine, Philadelphia, PA, United States.ORCID 0000-0003-3480-2661
J DaviesCollege of Arts and Sciences, University of Pennsylvania, Philadelphia, PA, United States.
A E LiebermanDepartment of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
J B MasonPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
A W ArmstrongDepartment of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.ORCID 0000-0003-0064-8707
A OgdieDepartment of Rheumatology, Perelman Center for Advanced Medicine, Philadelphia, PA, United States.ORCID 0000-0002-4639-0775
N N MehtaFAHA Section of Inflammation and Cardiometabolic Diseases, National Institute of Health, Bethesda, MD, United States.ORCID 0000-0003-4939-5130
J S BarbieriDepartment of Dermatology, Brigham and Women's Hospital, Boston, MA, United States.ORCID 0000-0002-5467-4102
R S BeidasDepartment of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.ORCID 0000-0001-6056-6071
University of Pennsylvania · USUniversity of the Sciences · USUniversity of Southern California · USUniversity of Pennsylvania Health System · US

Funding

Penn Dermatology Research Training ProgramT32AR007465 · NIAMS · UNIVERSITY OF PENNSYLVANIA · PI Elizabeth Anne Grice, David Joel Margolis · 1986 to 2026
$9.0M
Study Design and Data AnalysisP30AR069589 · NIAMS · UNIVERSITY OF PENNSYLVANIA · PI Elizabeth Anne Grice · 2016 to 2026
$8.6M
NIAMS NIH HHS P30 AR069589NIAMS NIH HHS T32 AR007465
6 · The paper itself

Abstract

Background: Psoriasis is an immune-mediated disease associated with excess risk for cardiovascular disease (CVD). Guidelines recognize psoriasis as a CVD risk enhancer; however, psoriasis patients often do not have CVD risk factors identified nor managed. Objective: This study examines strategies to improve CVD prevention care from the perspective of dermatologists and patients with psoriasis. Methods: Qualitative interviews were conducted using the Consolidated Framework for Implementation Research to examine the perspectives of physicians (N = 16) and patients with psoriatic disease (N = 16) on barriers/facilitators to CVD prevention. Interviews were transcribed and coded using an integrated approach designed to enhance reliability and validity using NVivo software. Results: We found three major themes suggesting areas to target for the future: (1) Appropriateness: perceptions of whether CVD care should be deployed in this setting by both clinicians and patients, (2) Feasibility: whether CVD prevention care could be integrated into the current structure of specialist practice, and (3) Care Coordination: an interest by all parties to better integrate a team approach in CVD preventative care to reduce duplicative efforts, work practically in an already existing system rather than reinventing the wheel, and progress with the patients' best interests in mind. Conclusions: These findings will inform the design of a clinical trial comparing the effectiveness of specialist clinician implementation of CVD guideline-based prevention care in patients with psoriasis. Ultimately, this study aims to increase the lifespan and health of patients living with psoriatic disease by decreasing barriers to their receiving appropriate CVD prevention care.

Indexed as

cardiovascular diseasecholesterolimplementation sciencepsoriasispsoriatic arthritisqualitative interviewsrisk reductionstatins

Identifiers

PMID38148879
PMCPMC10751045
OpenAlexW4282030017

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.